Olesen KKW, Pareek M, Madsen M, et al. - Researchers performed a comparison between diabetes and nondiabetes patients managed with Endeavor zotarolimus-eluting (ZES) or Cypher sirolimus-eluting coronary stents (SES), focusing on 10-year clinical outcomes. They examined 1,162 patients randomized to ZES (169 with diabetes) and 1,170 randomized to SES (168 with diabetes). Further stratification of the patients was done by diabetes status at the time of inclusion. Angiographic re-assessment 10 months following stent implantation was performed in a subgroup of patients with diabetes (n = 88). A combined end point of mortality or myocardial infarction, and the individual endpoints of death, myocardial infarction, and revascularization were assessed. Findings revealed there was a similar performance of SES and ZES, at 10 years, in patients with and without diabetes. They noted diabetes patients with ZES had more prevalence of coronary revascularization, this may, partially, have been associated with the angiographic follow-up performed in a subgroup of diabetes patients.